Company intelligence / Profile preview

Camallergy

Cambridge, United Kingdomcamallergy.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 2

Overview

Camallergy’s lead product, CA002, an oral immunotherapy using whole peanut protein, has demonstrated best-in-class safety and efficacy in over three hundred children during Phase II trials. The regimen showed high tolerability with a low withdrawal rate and reduced need for epinephrine compared to other therapies. The company’s cGMP-certified facility supports pivotal Phase III trials and early access programs. Camallergy aims to provide a safer and more effective treatment option for children with life-threatening food allergies.[1][5][7]

Therapeutic areas: Immunology
Modalities: Oral immunotherapyBiological drug (whole peanut protein)
Industry: Biotech

Drug pipeline

1 asset

CA002

Unknown

Beyond the preview

Go deeper on Camallergy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Camallergy.

Explore the full profile